Follicular Lymphoma: Clinical Features and Treatment

Hematology/Oncology Clinics of North America

Volumn 22, Issue 5, 2008, Pages 863-882

  Tan, Daryl ^a   Horning, Sandra J ^b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b STANFORD CANCER INSTITUTE   (United States)

Author keywords

Follicular; Indolent; Non Hodgkin's Lymphoma; Treatment

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE; BENDAMUSTINE; BLEOMYCIN; BORTEZOMIB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPRATUZUMAB; ETOPOSIDE; FLUDARABINE; GALIXIMAB; IBRITUMOMAB TIUXETAN; INTERFERON; LACTATE DEHYDROGENASE; LENALIDOMIDE; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNIMUSTINE; PREDNISONE; PROCARBAZINE; RITUXIMAB; SGN 40; TENIPOSIDE; THIOTEPA; TOSITUMOMAB I 131; VINCRISTINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ASCITES; BONE MARROW METASTASIS; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL TRANSFORMATION; CELLULAR IMMUNITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOPENIA; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLICULAR LYMPHOMA; FOLLICULAR LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOLOGY; HUMAN; HUMORAL IMMUNITY; IMMUNOCHEMISTRY; INCIDENCE; INTERNATIONAL PROGNOSTIC INDEX; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKEMIA; LOW DRUG DOSE; LYMPHADENOPATHY; MAINTENANCE THERAPY; MALIGNANT TRANSFORMATION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PARAMETER; PLEURA EFFUSION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIOIMMUNOTHERAPY; REVIEW; SINGLE DRUG DOSE; SPLENOMEGALY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME;

HUMANS; LYMPHOMA, FOLLICULAR; PROGNOSIS;

EID: 54049111503     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2008.07.013     Document Type: Review

References (109)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The non-Hodgkin's lymphoma classification project. Blood 89 (1997) 3909-3918
2. Horning S.J., and Rosenberg S.A. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 311 (1984) 1471-1475
3. Acker B., Hoppe R.T., Colby T.V., et al. Histologic conversion in the non-Hodgkin's lymphomas. J Clin Oncol 1 (1983) 11-16
4. Garvin A.J., Simon R.M., Osborne C.K., et al. An autopsy study of histologic progression in non-Hodgkin's lymphomas. 192 cases from the National Cancer Institute. Cancer 52 (1983) 393-398
5. Hubbard S.M., Chabner B.A., DeVita V.J., et al. Histologic progression in non-Hodgkin's lymphoma. Blood 59 (1982) 258-264
6. Swerdlow S.H. Pediatric follicular lymphomas, marginal zone lymphomas, and marginal zone hyperplasia. Am J Clin Pathol 122 Suppl (2004) S98-S109
7. Damaj G., Verkarre V., Delmer A., et al. Primary follicular lymphoma of the gastrointestinal tract: a study of 25 cases and a literature review. Ann Oncol 14 (2003) 623-629
8. López-Guillermo A., Montserrat E., Bosch F., et al. Applicability of the international index for aggressive lymphomas to patients with low-grade lymphoma. [see comments]. J Clin Oncol 12 (1994) 1343-1348
9. Solal-Celigny P., Roy P., Colombat P., et al. Follicular Lymphoma International Prognostic Index. Blood 104 (2004) 1258-1265
10. Buske C., Hoster E., Dreyling M., et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 108 (2006) 1504-1508
11. Marcus R., Imrie K., Belch A., et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105 (2005) 1417-1423
12. Hiddemann W., Kneba M., Dreyling M., et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106 (2005) 3725-3732
13. Federico M., Bellei M., Pro B., et al. Revalidation of FLIPI in patients with follicular lymphoma (FL) registered in the F2 study and treated upfront with immunochemotherapy. J Clin Oncol 25 (2006) [abstract 8008]
14. Brice P., Bastion Y., Lepage E., et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 15 (1997) 1110-1117
15. Salles G., Mounier N., De Guibert S., et al. Final analysis of the GELA-GOELAMS FL2000 study with a 5-year follow-up. Blood 110 (2007) 792A
16. Harris N.L., Jaffe E.S., Diebold J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol 17 (1999) 3835-3849
17. Hans C.P., Weisenburger D.D., Vose J.M., et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 101 (2003) 2363-2367
18. Horsman D.E., Connors J.M., Pantzar T., et al. Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18). Genes Chromosomes Cancer 30 (2001) 375-382
19. Dave S.S., Wright G., Tan B., et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351 (2004) 2159-2169
20. Farinha P., Masoudi H., Skinnider B.F., et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 106 (2005) 2169-2174
21. Lee A.M., Clear A.J., Calaminici M., et al. Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 24 (2006) 5052-5059
22. Glas A.M., Knoops L., Delahaye L., et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 25 (2007) 390-398
23. Cerhan J., Wang S., Maurer M., et al. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood 109 (2007) 5439-5446
24. Johnson P.W., Rohatiner A.Z., Whelan J.S., et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 13 (1995) 140-147
25. Horning S.J. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20 (1993) 75-88
26. Fisher R.I., LeBlanc M., Press O.W., et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23 (2005) 8447-8452
27. Swenson W.T., Wooldridge J.E., Lynch C.F., et al. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 23 (2005) 5019-5026
28. Liu Q., Fayad L., Cabanillas F., et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 24 (2006) 1582-1589
29. Tan D., Rosenberg S.A., Levy R., et al. Survival in follicular lymphoma: the Stanford experience, 1960-2003. Blood 110 (2007) 3428A
30. Yuen A.R., Kamel O.W., Halpern J., et al. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol 13 (1995) 1726-1733
31. Montoto S., Davies A.J., Matthews J., et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 25 (2007) 2426-2433
32. Tan D., Rosenberg S.A., Lavori P., et al. Improved prognosis after histologic transformation of follicular lymphoma: the Stanford experience 1960-2003. Programs and abstracts of the 10th International Conference on Malignant Lymphoma. Lugano (2008) p. 111.
33. Al-Tourah A.J., Savage K.J., Gill K.K., et al. Addition of rituximab to CHOP chemotherapy significantly improves survival of patients with transformed lymphoma. ASH Annual Meeting Abstracts 110 (2007) 790
34. Portlock C.S., and Rosenberg S.A. No initial therapy for stage III and IV non-Hodgkin's lymphomas of favorable histologic types. Ann Intern Med 90 (1979) 10-13
35. Ardeshna K.M., Smith P., Norton A., et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 362 (2003) 516-522
36. Young R.C., Longo D.L., Glatstein E., et al. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol 25 (1988) 11-16
37. Portlock C.S., and Rosenberg S.A. Combination chemotherapy with cyclophosphamide, vincristine, and prednisone in advanced non-Hodgkin's lymphomas. Cancer 37 (1976) 1275-1282
38. Gallagher C.J., Gregory W.M., Jones A.E., et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 4 (1986) 1470-1480
39. Kimby E., Björkholm M., Gahrton G., et al. Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol 5 Suppl 2 (1994) 67-71
40. Peterson B.A., Petroni G.A., and Frizzera G. Prolonged single agent versus combination chemotherapy in indolent follicular lymphomas. A study of the Cancer and Leukemia Group B. J Clin Oncol 21 (2002) 5-15
41. Solal-Céligny P., Brice P., Brousse N., et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 14 (1996) 514-519
42. McLaughlin P., Hagemeister F.B., Romaguera J.E., et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 14 (1996) 1262-1268
43. Velasquez W.S., Lew D., Grogan T.M., et al. Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501. J Clin Oncol 21 (2003) 1996-2003
44. Forstpointner R., Dreyling M., Repp R., et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104 (2004) 3064-3071
45. Hagenbeek A., Eghbali H., Monfardini S., et al. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant non-Hodgkin's lymphoma. J Clin Oncol 24 (2006) 1590-1596
46. Maloney D.G., Grillo-López A.J., Bodkin D.J., et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15 (1997) 3266-3274
47. McLaughlin P., Grillo-Lopez A.J., Link B.K., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16 (1998) 2825-2833
48. Hainsworth J.D., Litchy S., Burris III H.A., et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 20 (2002) 4261-4267
49. Colombat P., Salles G., Brousse N., et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97 (2001) 101-106
50. Colombat P., Brousse N., Morschhauser F., et al. Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): survival analyses with extended follow-up (F/Up) of 7 years. ASH Annual Meeting Abstracts 108 (2006) 486
51. Ghielmini M., Schmitz S.F., Cogliatti S.B., et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 103 (2004) 4416-4423
52. Kahl B.S. Eastern Cooperative Oncology Group 4402: Rituximab Extended Schedule or Retreatment Trial (RESORT). Clin Lymphoma Myeloma 6 (2006) 423-426
53. Herold M., Haas A., Srock S., et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German study group hematology and oncology study. J Clin Oncol 25 (2007) 1986-1992
54. Marcus R., Solal-Celigny P., Imrie K., et al. MabThera (rituximab) plus cyclophosphamide, vincristine and prednisone (CVP) chemotherapy improves survival in previously untreated patients with advanced follicular non-Hodgkins lymphoma. [abstract]. Blood 108 (2006) 481
55. Hochster H.S., Weller E., Gascoyne R.D., et al. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial. [abstract]. Blood 106 (2005) 349
56. van Oers M.H., Klasa R., Marcus R.E., et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 108 (2006) 3295-3301
57. Kaminski M.S., Zelenetz A.D., Press O.W., et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19 (2001) 3918-3928
58. Witzig T.E., Gordon L.I., Cabanillas F., et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20 (2002) 2453-2463
59. Witzig T.E., White C.A., Wiseman G.A., et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 17 (1999) 3793-3803
60. Vose J.M., Wahl R.L., Saleh M., et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 18 (2000) 1316-1323
61. Witzig T.E., Flinn I.W., Gordon L.I., et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20 (2002) 3262-3269
62. Horning S.J., Lucas J.B., Younes A., et al. Iodine-131 tositumomab for non-Hodgkin's lymphoma (NHL) patients who progressed after treatment with rituximab: results of a multi-center phase II study. Blood 96 (2000) 2184A
63. Kaminski M.S., Tuck M., Estes J., et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352 (2005) 441-449
64. Press O.W., Unger J.M., Braziel R.M., et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 102 (2003) 1606-1612
65. Leonard J.P., Coleman M., Kostakoglu L., et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 23 (2005) 5696-5704
66. Hagenbeek A., Bischof-Delaloye A., Radford J.A., et al. 90Y-Ibritumomab tiuxetan (Zevalin(R)) consolidation of first remission in advanced stage follicular non-Hodgkin's lymphoma: first results of the international randomized phase 3 First-Line Indolent Trial (FIT) in 414 patients. Blood 110 (2007) 643
67. Freedman A.S., Gribben J.G., Neuberg D., et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 88 (1996) 2780-2786
68. Horning S.J., Negrin R.S., Hoppe R.T., et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood 97 (2001) 404-409
69. Colombat P., Cornillet P., Deconinck E., et al. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study. Bone Marrow Transplant 26 (2000) 971-977
70. Corradini P., Ladetto M., Zallio F., et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol 22 (2004) 1460-1468
71. Sebban C., Mounier N., Brousse N., et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 108 (2006) 2540-2544
72. Deconinck E., Foussard C., Milpied N., et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 105 (2005) 3817-3823
73. Lenz G., Dreyling M., Schiegnitz E., et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104 (2004) 2667-2674
74. Hsu F.J., Caspar C.B., Czerwinski D., et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood 89 (1997) 3129-3135
75. Levy R., Robertson M.J., Leonard J., et al. Results of a phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype conjugated to KLH with GM-CSF compared to non-specific immunotherapy, KLH, with GM-CSF in patients with follicular non-Hodgkin's lymphoma. Programs and abstracts of the 10th International Conference on Malignant Lymphoma. Lugano (2008) p. 101
76. Favrille announces results from phase 3 registration trial of Specifid in patients with follicular B-cell non-Hodgkin's lymphoma, 2008. Available at: http://www.favrille.com/trials/phase-3-clinical-trial-summary.htm.
77. Ai W.Z., Tibshirani R., Taidi B., et al. Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma. ASH Annual Meeting Abstracts 110 (2007) 647
78. Anderson T., Chabner B.A., Young R.C., et al. Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute. Cancer 50 (1982) 2699-2707
79. Mac Manus M.P., and Hoppe R.T. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 14 (1996) 1282-1290
80. Wilder R.B., Jones D., Tucker S.L., et al. Long-term results with radiotherapy for stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys 51 (2001) 1219-1227
81. Pendlebury S., el Awadi M., Ashley S., et al. Radiotherapy results in early stage low grade nodal non-Hodgkin's lymphoma. Radiother Oncol 36 (1995) 167-171
82. Guadagnolo B.A., Li S., Neuberg D., et al. Long-term outcome and mortality trends in early-stage, grade 1-2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys 64 (2006) 928-934
83. Peterson P.M., Gaspodarowicz M., and Tsang R. Long term outcome in stage I and II follicular lymphoma following treatment with involved field radiation therapy alone. J Clin Oncol 22 14S (2004) 653s
84. Seymour J.F., Pro B., Fuller L.M., et al. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. J Clin Oncol 21 (2003) 2115-2122
85. Wirth A., Foo M., Seymour J.F., et al. Impact of [18F] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 71 (2008) 213-219
86. Davis T.A., Grillo-Lopez A.J., White C.A., et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 18 (2000) 3135-3143
87. Horning S.J., Younes A., Jain V., et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 23 (2005) 712-719
88. 131 tositumomab. Blood 105 12 (2005) 4576-4582
89. Roboz G.J., Bennett J.M., Coleman M., et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma. Leuk Res 31 (2007) 1141-1144
90. Tse W.W., Lazarus H.M., and Van Besien K. Stem cell transplantation in follicular lymphoma: progress at last?. Bone Marrow Transplant 34 (2004) 929-938
91. Montoto S., Canals C., Rohatiner A.Z., et al. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia 21 (2007) 2324-2331
92. Freedman A.S., Neuberg D., Mauch P., et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 94 (1999) 3325-3333
93. Schouten H.C., Kvaloy S., Sydes M., et al. The CUP trial: a randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 11 (2000) 91-94
94. Rohatiner A.Z., Nadler L., Davies A.J., et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 25 (2007) 2554-2559
95. van Besien K., Loberiza Jr. F.R., Bajorunaite R., et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 102 (2003) 3521-3529
96. Toze C.L., Barnett M.J., Connors J.M., et al. Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation. Br J Haematol 127 (2004) 311-321
97. Marks D.I., Lush R., Cavenagh J., et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 100 (2002) 3108-3114
98. Mandigers C.M., Verdonck L.F., Meijerink J.P., et al. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant 32 (2003) 1159-1163
99. Khouri I.F., Saliba R.M., Lee M.C., et al. Longer follow-up confirms a low relapse rate after non-myeloablative allogeneic transplantation for non-Hodgkin's lymphoma, including patients with PET or gallium-avid disease. Blood 106 (2005) A44
100. Khouri I.F., Saliba R.M., Giralt S.A., et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98 (2001) 3595-3599
101. Khouri I.F., Saliba R.M., Korbling M., et al. Nonmyeloablative allogeneic transplantation (NMT) for relapsed follicular lymphoma (FL): continuous complete remission with longer follow-up. ASH Annual Meeting Abstracts 110 (2007) 485
102. Friedberg J.W., Cohen P., Chen L., et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 26 (2008) 204-210
103. Rummel M.J., von Gruenhagen U., Niederle N., et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas-first interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). ASH Annual Meeting Abstracts 110 (2007) 385
104. O'Connor O.A. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma. Clin Lymphoma Myeloma 6 (2005) 191-199
105. Czuczman M.S., Thall A., Witzig T.E., et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 23 (2005) 4390-4398
106. Leonard J.P., Friedberg J.W., Younes A., et al. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol 18 (2007) 1216-1223
107. Leonard J.P., Coleman M., Ketas J.C., et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 21 (2003) 3051-3059
108. Leonard J.P., Coleman M., Ketas J., et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 23 (2005) 5044-5051
109. Witzig T.E., Vose J.M., Moore T.D., et al. Results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory indolent non-Hodgkin's lymphoma. ASH Annual Meeting Abstracts 110 (2007) 2560